Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

Berenberg initiates coverage of GB Group at 'buy'

(Sharecast News) - Berenberg initiated coverage of GB Group on Thursday with a 'buy' rating and 340p price target. GB Group (GBG) operates in the identity verification, fraud prevention and location intelligence markets.

Berenberg said the company's cloud-native software uses data obtained from hundreds of providers to help businesses verify the location, identity, credentials and legitimacy of individuals.

"GBG has a long track record of organic and acquisition-driven growth, and was a significant beneficiary of the changes in consumer behaviour during the Covid-19 pandemic," it said.

"However, the business has since struggled to return to material growth, with its share price still down 70% from its October 2021 peak.

"While GBG's H225 was slightly weaker than anticipated, we have reviewed its growth credentials and think the recent product developments and ongoing reworking of its go-to-market strategy provide the potential for improvements to its organic growth rate and margins."

At 1055 BST, the shares were up 1.8% at 285.50p.

Share this article

Related Sharecast Articles

GSK gets preliminary nod for two respiratory drugs in Europe
(Sharecast News) - GSK said on Friday afternoon that two of its respiratory medicines had received positive opinions from the European Medicines Agency's Committee for Medicinal Products for Human Use, bringing the company closer to potential approvals across severe asthma, chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease.
Shore Capital hails improved US biotech funding environment for hVIVO
(Sharecast News) - Shares in AIM-listed hVIVO were continuing their recent surge on the back of encouraging signs from the US biotech market, which broker Shore Capital said has created a "much more favourable environment" for the company.
Weir to buy remaining 50% stake in Chile JV ESEL for £56m
(Sharecast News) - Weir said on Friday that it has agreed to buy the remaining 50% share of its Chile-based joint venture ESEL for a sterling equivalent purchase price of £56m.
Jefferies downgrades Whitbread, upgrades IHG
(Sharecast News) - Jefferies downgraded Whitbread to 'hold' from 'buy' on Friday as it applied the reverse upgrade to InterContinental Hotels.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.